- Home
- UHG vs SGMO Comparison
UHG vs SGMO Comparison
Compare UHG & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- SGMO
- Stock Information
- Founded
- UHG 2004
- SGMO 1995
- Country
- UHG United States
- SGMO United States
- Employees
- UHG N/A
- SGMO N/A
- Industry
- UHG Homebuilding
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHG Consumer Discretionary
- SGMO Health Care
- Exchange
- UHG Nasdaq
- SGMO Nasdaq
- Market Cap
- UHG 152.4M
- SGMO 122.8M
- IPO Year
- UHG N/A
- SGMO 2000
- Fundamental
- Price
- UHG $3.31
- SGMO $0.46
- Analyst Decision
- UHG
- SGMO Buy
- Analyst Count
- UHG 0
- SGMO 6
- Target Price
- UHG N/A
- SGMO $4.50
- AVG Volume (30 Days)
- UHG 338.1K
- SGMO 4.1M
- Earning Date
- UHG 08-07-2025
- SGMO 08-05-2025
- Dividend Yield
- UHG N/A
- SGMO N/A
- EPS Growth
- UHG N/A
- SGMO N/A
- EPS
- UHG 0.76
- SGMO N/A
- Revenue
- UHG $449,877,017.00
- SGMO $63,756,000.00
- Revenue This Year
- UHG N/A
- SGMO N/A
- Revenue Next Year
- UHG N/A
- SGMO N/A
- P/E Ratio
- UHG $4.35
- SGMO N/A
- Revenue Growth
- UHG 5.24
- SGMO 239.92
- 52 Week Low
- UHG $1.60
- SGMO $0.30
- 52 Week High
- UHG $6.93
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- UHG 56.38
- SGMO 38.27
- Support Level
- UHG $3.10
- SGMO $0.49
- Resistance Level
- UHG $3.70
- SGMO $0.51
- Average True Range (ATR)
- UHG 0.41
- SGMO 0.04
- MACD
- UHG -0.04
- SGMO 0.01
- Stochastic Oscillator
- UHG 19.54
- SGMO 6.25
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.